Copyright Reports & Markets. All rights reserved.

Global Parkinson Disease Drug Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Parkinson Disease Drug by Type
    • 1.3.1 Overview: Global Parkinson Disease Drug Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Parkinson Disease Drug Consumption Value Market Share by Type in 2025
    • 1.3.3 Sinemet-CR
    • 1.3.4 Trastal
    • 1.3.5 Madopar
    • 1.3.6 COMT Inhibitor
    • 1.3.7 Other
  • 1.4 Global Parkinson Disease Drug Market by Application
    • 1.4.1 Overview: Global Parkinson Disease Drug Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Under 40 Years Old
    • 1.4.3 40-65 Years Old
    • 1.4.4 Above 65 Years Old
  • 1.5 Global Parkinson Disease Drug Market Size & Forecast
  • 1.6 Global Parkinson Disease Drug Market Size and Forecast by Region
    • 1.6.1 Global Parkinson Disease Drug Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Parkinson Disease Drug Market Size by Region, (2021-2032)
    • 1.6.3 North America Parkinson Disease Drug Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Parkinson Disease Drug Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Parkinson Disease Drug Market Size and Prospect (2021-2032)
    • 1.6.6 South America Parkinson Disease Drug Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Parkinson Disease Drug Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Merck
    • 2.1.1 Merck Details
    • 2.1.2 Merck Major Business
    • 2.1.3 Merck Parkinson Disease Drug Product and Solutions
    • 2.1.4 Merck Parkinson Disease Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Merck Recent Developments and Future Plans
  • 2.2 Akorn
    • 2.2.1 Akorn Details
    • 2.2.2 Akorn Major Business
    • 2.2.3 Akorn Parkinson Disease Drug Product and Solutions
    • 2.2.4 Akorn Parkinson Disease Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Akorn Recent Developments and Future Plans
  • 2.3 GSK
    • 2.3.1 GSK Details
    • 2.3.2 GSK Major Business
    • 2.3.3 GSK Parkinson Disease Drug Product and Solutions
    • 2.3.4 GSK Parkinson Disease Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 GSK Recent Developments and Future Plans
  • 2.4 Novartis
    • 2.4.1 Novartis Details
    • 2.4.2 Novartis Major Business
    • 2.4.3 Novartis Parkinson Disease Drug Product and Solutions
    • 2.4.4 Novartis Parkinson Disease Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Novartis Recent Developments and Future Plans
  • 2.5 Boehringer Ingelheim
    • 2.5.1 Boehringer Ingelheim Details
    • 2.5.2 Boehringer Ingelheim Major Business
    • 2.5.3 Boehringer Ingelheim Parkinson Disease Drug Product and Solutions
    • 2.5.4 Boehringer Ingelheim Parkinson Disease Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Boehringer Ingelheim Recent Developments and Future Plans
  • 2.6 Teva Pharmaceutical
    • 2.6.1 Teva Pharmaceutical Details
    • 2.6.2 Teva Pharmaceutical Major Business
    • 2.6.3 Teva Pharmaceutical Parkinson Disease Drug Product and Solutions
    • 2.6.4 Teva Pharmaceutical Parkinson Disease Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Teva Pharmaceutical Recent Developments and Future Plans
  • 2.7 Abbvie
    • 2.7.1 Abbvie Details
    • 2.7.2 Abbvie Major Business
    • 2.7.3 Abbvie Parkinson Disease Drug Product and Solutions
    • 2.7.4 Abbvie Parkinson Disease Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Abbvie Recent Developments and Future Plans
  • 2.8 Kyowa Hakko Kirin Pharma
    • 2.8.1 Kyowa Hakko Kirin Pharma Details
    • 2.8.2 Kyowa Hakko Kirin Pharma Major Business
    • 2.8.3 Kyowa Hakko Kirin Pharma Parkinson Disease Drug Product and Solutions
    • 2.8.4 Kyowa Hakko Kirin Pharma Parkinson Disease Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Kyowa Hakko Kirin Pharma Recent Developments and Future Plans
  • 2.9 Astellas Pharma
    • 2.9.1 Astellas Pharma Details
    • 2.9.2 Astellas Pharma Major Business
    • 2.9.3 Astellas Pharma Parkinson Disease Drug Product and Solutions
    • 2.9.4 Astellas Pharma Parkinson Disease Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Astellas Pharma Recent Developments and Future Plans
  • 2.10 Desitin Arzneimittel
    • 2.10.1 Desitin Arzneimittel Details
    • 2.10.2 Desitin Arzneimittel Major Business
    • 2.10.3 Desitin Arzneimittel Parkinson Disease Drug Product and Solutions
    • 2.10.4 Desitin Arzneimittel Parkinson Disease Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Desitin Arzneimittel Recent Developments and Future Plans
  • 2.11 Endo Pharmaceuticals
    • 2.11.1 Endo Pharmaceuticals Details
    • 2.11.2 Endo Pharmaceuticals Major Business
    • 2.11.3 Endo Pharmaceuticals Parkinson Disease Drug Product and Solutions
    • 2.11.4 Endo Pharmaceuticals Parkinson Disease Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Endo Pharmaceuticals Recent Developments and Future Plans
  • 2.12 F.Hoffmann-La Roche
    • 2.12.1 F.Hoffmann-La Roche Details
    • 2.12.2 F.Hoffmann-La Roche Major Business
    • 2.12.3 F.Hoffmann-La Roche Parkinson Disease Drug Product and Solutions
    • 2.12.4 F.Hoffmann-La Roche Parkinson Disease Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 F.Hoffmann-La Roche Recent Developments and Future Plans
  • 2.13 H.Lundbeck
    • 2.13.1 H.Lundbeck Details
    • 2.13.2 H.Lundbeck Major Business
    • 2.13.3 H.Lundbeck Parkinson Disease Drug Product and Solutions
    • 2.13.4 H.Lundbeck Parkinson Disease Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 H.Lundbeck Recent Developments and Future Plans
  • 2.14 Valeant
    • 2.14.1 Valeant Details
    • 2.14.2 Valeant Major Business
    • 2.14.3 Valeant Parkinson Disease Drug Product and Solutions
    • 2.14.4 Valeant Parkinson Disease Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Valeant Recent Developments and Future Plans
  • 2.15 Apokyn
    • 2.15.1 Apokyn Details
    • 2.15.2 Apokyn Major Business
    • 2.15.3 Apokyn Parkinson Disease Drug Product and Solutions
    • 2.15.4 Apokyn Parkinson Disease Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Apokyn Recent Developments and Future Plans
  • 2.16 Orion
    • 2.16.1 Orion Details
    • 2.16.2 Orion Major Business
    • 2.16.3 Orion Parkinson Disease Drug Product and Solutions
    • 2.16.4 Orion Parkinson Disease Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 Orion Recent Developments and Future Plans
  • 2.17 Stada Arzneimittel
    • 2.17.1 Stada Arzneimittel Details
    • 2.17.2 Stada Arzneimittel Major Business
    • 2.17.3 Stada Arzneimittel Parkinson Disease Drug Product and Solutions
    • 2.17.4 Stada Arzneimittel Parkinson Disease Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.17.5 Stada Arzneimittel Recent Developments and Future Plans
  • 2.18 US WorldMeds
    • 2.18.1 US WorldMeds Details
    • 2.18.2 US WorldMeds Major Business
    • 2.18.3 US WorldMeds Parkinson Disease Drug Product and Solutions
    • 2.18.4 US WorldMeds Parkinson Disease Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.18.5 US WorldMeds Recent Developments and Future Plans
  • 2.19 Bausch Health
    • 2.19.1 Bausch Health Details
    • 2.19.2 Bausch Health Major Business
    • 2.19.3 Bausch Health Parkinson Disease Drug Product and Solutions
    • 2.19.4 Bausch Health Parkinson Disease Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.19.5 Bausch Health Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Parkinson Disease Drug Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Parkinson Disease Drug by Company Revenue
    • 3.2.2 Top 3 Parkinson Disease Drug Players Market Share in 2025
    • 3.2.3 Top 6 Parkinson Disease Drug Players Market Share in 2025
  • 3.3 Parkinson Disease Drug Market: Overall Company Footprint Analysis
    • 3.3.1 Parkinson Disease Drug Market: Region Footprint
    • 3.3.2 Parkinson Disease Drug Market: Company Product Type Footprint
    • 3.3.3 Parkinson Disease Drug Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Parkinson Disease Drug Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Parkinson Disease Drug Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Parkinson Disease Drug Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Parkinson Disease Drug Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Parkinson Disease Drug Consumption Value by Type (2021-2032)
  • 6.2 North America Parkinson Disease Drug Market Size by Application (2021-2032)
  • 6.3 North America Parkinson Disease Drug Market Size by Country
    • 6.3.1 North America Parkinson Disease Drug Consumption Value by Country (2021-2032)
    • 6.3.2 United States Parkinson Disease Drug Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Parkinson Disease Drug Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Parkinson Disease Drug Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Parkinson Disease Drug Consumption Value by Type (2021-2032)
  • 7.2 Europe Parkinson Disease Drug Consumption Value by Application (2021-2032)
  • 7.3 Europe Parkinson Disease Drug Market Size by Country
    • 7.3.1 Europe Parkinson Disease Drug Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Parkinson Disease Drug Market Size and Forecast (2021-2032)
    • 7.3.3 France Parkinson Disease Drug Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Parkinson Disease Drug Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Parkinson Disease Drug Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Parkinson Disease Drug Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Parkinson Disease Drug Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Parkinson Disease Drug Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Parkinson Disease Drug Market Size by Region
    • 8.3.1 Asia-Pacific Parkinson Disease Drug Consumption Value by Region (2021-2032)
    • 8.3.2 China Parkinson Disease Drug Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Parkinson Disease Drug Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Parkinson Disease Drug Market Size and Forecast (2021-2032)
    • 8.3.5 India Parkinson Disease Drug Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Parkinson Disease Drug Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Parkinson Disease Drug Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Parkinson Disease Drug Consumption Value by Type (2021-2032)
  • 9.2 South America Parkinson Disease Drug Consumption Value by Application (2021-2032)
  • 9.3 South America Parkinson Disease Drug Market Size by Country
    • 9.3.1 South America Parkinson Disease Drug Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Parkinson Disease Drug Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Parkinson Disease Drug Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Parkinson Disease Drug Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Parkinson Disease Drug Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Parkinson Disease Drug Market Size by Country
    • 10.3.1 Middle East & Africa Parkinson Disease Drug Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Parkinson Disease Drug Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Parkinson Disease Drug Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Parkinson Disease Drug Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Parkinson Disease Drug Market Drivers
  • 11.2 Parkinson Disease Drug Market Restraints
  • 11.3 Parkinson Disease Drug Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Parkinson Disease Drug Industry Chain
  • 12.2 Parkinson Disease Drug Upstream Analysis
  • 12.3 Parkinson Disease Drug Midstream Analysis
  • 12.4 Parkinson Disease Drug Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Parkinson Disease Drug market size was valued at US$ 6724 million in 2025 and is forecast to a readjusted size of US$ 10080 million by 2032 with a CAGR of 6.0% during review period.
    Most people with Parkinson"s disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.
    Global Parkinson Disease Drug key players include Merck, Akorn, GSK, Boehringer Ingelheim, Teva Pharmaceutical, etc.
    This report is a detailed and comprehensive analysis for global Parkinson Disease Drug market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Parkinson Disease Drug market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Parkinson Disease Drug market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Parkinson Disease Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Parkinson Disease Drug market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Parkinson Disease Drug
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Parkinson Disease Drug market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck, Akorn, GSK, Novartis, Boehringer Ingelheim, Teva Pharmaceutical, Abbvie, Kyowa Hakko Kirin Pharma, Astellas Pharma, Desitin Arzneimittel, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Parkinson Disease Drug market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Sinemet-CR
    Trastal
    Madopar
    COMT Inhibitor
    Other
    Market segment by Application
    Under 40 Years Old
    40-65 Years Old
    Above 65 Years Old
    Market segment by players, this report covers
    Merck
    Akorn
    GSK
    Novartis
    Boehringer Ingelheim
    Teva Pharmaceutical
    Abbvie
    Kyowa Hakko Kirin Pharma
    Astellas Pharma
    Desitin Arzneimittel
    Endo Pharmaceuticals
    F.Hoffmann-La Roche
    H.Lundbeck
    Valeant
    Apokyn
    Orion
    Stada Arzneimittel
    US WorldMeds
    Bausch Health
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Parkinson Disease Drug product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Parkinson Disease Drug, with revenue, gross margin, and global market share of Parkinson Disease Drug from 2021 to 2026.
    Chapter 3, the Parkinson Disease Drug competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Parkinson Disease Drug market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Parkinson Disease Drug.
    Chapter 13, to describe Parkinson Disease Drug research findings and conclusion.

    Buy now